Unmutated patients on venetoclax?: I just... - CLL Support

CLL Support

24,063 members40,930 posts

Unmutated patients on venetoclax?

HikerBiker profile image
11 Replies

I just watched the video "Evolving Front-Line Therapy in Chronic Lymphocytic Leukemia" posted by EugeneL2. In it, she refers to the trial where patients on venetoclax + obinutuzumab had much better results than those on chlorambucil + obinutuzumab. However, she also noted that mutated patients on both treatments fared better than unmutated patients.

As an unmutated patient who decided to go with venetoclax over acalabrutinib I wonder about the unmutated factor. Don't unmutated patients do equally well on the BTK inhibitors?

Written by
HikerBiker profile image
HikerBiker
To view profiles and participate in discussions please or .
Read more about...
11 Replies
cajunjeff profile image
cajunjeff

According to the article below, the answer to your question is yes. I remember reading somewhere, however, that while ibrutinib works well with 17p Cll too, 17p still carries some additional risk even with ibrutinib.

oncotherapynetwork.com/leuk...

MaxSmart profile image
MaxSmart

Hi Hiker Biker, I just watch the video myself because I am unmutated. I didn’t really get a clear answer watching the video but then I watch a second video where Dr. Lamanna clearly states that unmutated don’t do as well long term as mutated. But looking at it more closely she’s using a slide dated 1999. It’s around 18 minutes into the video. Around 24 minute mark she says mutated and unmutated do equally well on Venetoclax.

youtu.be/wODcksQ5SoE

HikerBiker profile image
HikerBiker in reply toMaxSmart

Interesting that Dr. Lamanna came to that conclusion from the same study as Dr. Woyach was referring to in her presentation. Here is the slide from Dr. Woyach's presentation, and you can see there is a clear difference between mutated and unmutated patients in the Murano study: drive.google.com/file/d/1Uu...

Canuck901 profile image
Canuck901

Yeah unmutated 17p and TP53 are the unfavourable high risk markers and usually have shorter remissions compared to others without the markers. Also everyone’s CLL is different and some people have had good remissions from I plus V and A plus V I believe

Seems to be good synergies between both together

Newer combos seem to be much better for all favourable and unfavourable markers

targetedonc.com/view/acalab...

Shepherd777 profile image
Shepherd777

Mutated was always better than unmutated until Imbruvica and Venetoclax came along. These two fairly new novel oral agents became a real game changer leaving the mutated versus unmutated question basically a no burger.

I realize that there are some other details undetected so far, but deep in the genome that determine on occasion that a 13q patient responds to nothing and on the other hand a small number of 17P TP53 patients stay in watch and wait for 10 years or more. However for the most part even unmutated Trisomy 12, 11Q and even 17P respond positively to these new agents.

Tton46 profile image
Tton46

Thank you !

MaxSmart profile image
MaxSmart

On the Dr. Lamanna video she also talks about the fitness level of the patient. On this forum we discuss medical markers and not that much about fitness levels, but that factor can make a big difference.

bennevisplace profile image
bennevisplace

As I understand it BTK inhibitors have good synergy with BCL2 inhibitors. See phase 2 study on high-risk patients of Ibrutinib-Venetoclax as first line therapy nejm.org/doi/full/10.1056/N...

17Pisme profile image
17Pisme

Being a 17P/TP53 and having been on I for 4 years I can confirm that both I & V somewhat flattens the CLL field. However, as was expected, I ran out of gas with I & switched to V which has been great & without the side effects (bleeding face, skin rashes, staph infections, etc.).

hanskloss profile image
hanskloss

I am unmutated and on Venatoclax for 3 years. Doing very well and hope this continues...never been on BTK...

Tapps profile image
Tapps

Unmutated patients have to be aware of their treatment requirements. The new BTK seem be fairing well for Unmutated patients.

Not what you're looking for?

You may also like...

Adding Venetoclax to Obinutuzumab Prolongs Progression-Free Survival in Previously Untreated CLL

Dated 1st September 2019 In a phase III trial of patients with previously untreated CLL...
Jm954 profile image
Administrator

Scottish Medicines Agency has decided in favour of Venetoclax plus Obintuzumab for some patients.

The SMC has accepted venetoclax in combination with obinutuzumab for use in certain patients. There...
Jm954 profile image
Administrator

Frontline Venetoclax/Obinutuzumab Approved in Europe for CLL

In some welcome good news, "The European Commission has approved a fixed-dose combination of...
AussieNeil profile image
Partner

Venetoclax Approved!

Received good news today. the Insurance company approved Venetoclax for the treatment of my...
ReneeSusan profile image

AbbVie Pharm--positive phase 3 for CLL!

Hey, all, see this article about AbbVie pharma! AbbVie Sees Continued Positive Results for...
Vlaminck profile image

Moderation team

See all
lankisterguy profile image
lankisterguyAdministrator
CLLerinOz profile image
CLLerinOzAdministrator
SofiaDeo profile image
SofiaDeoAdministrator

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.